Peptavo is Jointly Accredited for 20 CME hours. Learn more about accreditation
PEPTAVO
The Stack Source LLC1908 E 11th Street Austin, TX 78702support@peptavo.com(512) 827-8158DBA: Peptavo
Peptavo is Jointly Accredited for 20 CME hours. Learn more about accreditation
Get volume discounts if you are getting 3 or more clinicians certified
Book a Call
Every peptide compounding pharmacy says it is the careful one. Here is how to find out: the license, the inspection file, the accreditation, the certificate of analysis, and whether the peptide itself is legal to compound this month.
A peptide compounding pharmacy earns your prescriptions by producing five documents, quickly: an active license in your patient's state, an inspection file with nothing left open, an accreditation someone else verified, a certificate of analysis for the lot in your patient's vial, and the FDA source that says the peptide is lawful to compound today.
Everything below is the long version of that paragraph: what the five documents prove, where to check them yourself, and the answers that should end the conversation.
Status as of October 12, 2026. FDA's compounding advisory committee recommended six peptide families for the 503A Bulks List in July 2026. FDA has not published a proposed rule, so none of them has been added. Our US legality guide tracks that process, and we update both pages when it moves.
A compounding pharmacy prepares a medication for one named patient from bulk ingredients, in a strength or form no approved product offers. For peptides that nearly always means a sterile injectable made from lyophilized powder, which lands the work under the strictest standards in pharmacy.
Compounded drugs are not FDA-approved. Nobody at FDA reviews a compounded peptide for safety, effectiveness, or quality before it ships. With an approved drug, the manufacturer carries that burden under FDA inspection. With a compounded one, the pharmacy carries it under its state board, and you carry the judgment that brought the two together. Hence the paperwork.
Every compounding pharmacy in the country operates under one of two sections of the Food, Drug, and Cosmetic Act. The letter changes how you order, who inspects, and what the pharmacy may make.
| 503A compounding pharmacy | 503B outsourcing facility | |
|---|---|---|
| Prescription | One named patient per prescription | May supply office stock without a patient name |
| Primary oversight | State board of pharmacy, with FDA surveillance and for-cause visits | FDA, on a risk-based inspection schedule |
| Quality standard | USP chapters 795, 797, and 800 as the state adopts them | Current good manufacturing practice, the same framework drug manufacturers follow |
| Bulk ingredient rules | USP or NF monograph, component of an approved drug, or the 503A Bulks List | The separate 503B bulks list and FDA's drug shortage list |
| Where to verify | Your state board's license lookup | FDA's registered outsourcing facilities list |
Most peptide prescriptions run through 503A pharmacies, because a 503A pharmacy can serve an individual patient from a nominated bulk substance while FDA is still making up its mind. A 503B facility fits when you want vials on the shelf for in-clinic administration, and the price of that convenience is a shorter list of peptides it may make.
Ask which section covers your order before anything else. Plenty of pharmacies hold both a 503A license and a 503B registration, and the labeling, the paperwork, and the legal status of your product differ depending on which door it leaves through.
Begin with the board of pharmacy in the state where your patient lives, since that is the license that has to exist for the pharmacy to ship there. Every board publishes a lookup. Confirm the license is active, covers the pharmacy's current address, and carries no discipline. An out-of-state pharmacy needs a nonresident license in your patient's state on top of its home license.
For a 503B facility, FDA keeps a registered outsourcing facilities list that updates weekly. Each row shows the last inspection date, whether investigators issued a Form 483 of observations, whether a recall followed, and whether FDA took further action. A surprising number of facilities read "not yet inspected," which sounds clean and means nothing. An inspected facility with a closed file beats one FDA has never visited.
Many states license nonresident pharmacies on the strength of an inspection by the National Association of Boards of Pharmacy, through its Verified Pharmacy Program. If a pharmacy mentions a VPP inspection, ask for the date and whether any findings were still open at its last license renewal.
Licensure is the floor. Accreditation is a third party checking that the compounding practice matches the USP chapters the website brags about.
PCAB accreditation, run by the Accreditation Commission for Health Care, is the badge you will see most often. It evaluates compliance with USP 795 for nonsterile compounding, USP 797 for sterile compounding, and USP 800 for hazardous drugs. NABP runs its own Compounding Pharmacy Accreditation, good for three years, which requires a VPP inspection within the previous six months and maps to the same chapters.
Either one is meaningful. Neither is required by law, and competent pharmacies exist without them, so treat accreditation as a strong positive rather than a filter. What you should refuse is the bare word "accredited." Ask which program, when it was renewed, and whether the scope covers sterile compounding. Then confirm it in the accreditor's directory rather than on the pharmacy's homepage.
Under section 503A, a bulk drug substance must come from a manufacturer registered with FDA and arrive with a valid certificate of analysis. Both are legal conditions, and a pharmacy should be able to show you both for any lot it dispenses to your patient.
Ask for the certificate for your patient's lot, then actually read it. It should name the supplier, the lot number, the identity test and result, purity by HPLC, and a date. A certificate that reports identity and purity but no endotoxin or sterility result describes a raw material, which is fine, provided the pharmacy runs those tests on the finished preparation.
Two things a certificate of analysis will never tell you. It says nothing about what happened to the powder after it reached the pharmacy. And a certificate from a "research-grade" peptide vendor does not turn that vendor into an FDA-registered establishment. If the pharmacy cannot name the registered manufacturer behind the lot, the preparation fails the 503A conditions, however tidy the PDF looks.
An injectable peptide is a sterile preparation, and USP General Chapter 797 governs how one gets made: cleanroom classification, certification of the engineering controls, staff training and competency, environmental monitoring, and how long the finished product may be used.
A pharmacy that compounds peptides should answer four questions without opening a binder. Where is sterile compounding done, and what ISO class are the primary engineering control and the room around it? When were those controls last certified, given that USP 797 requires it at least every six months? Who performs sterility and endotoxin testing on finished preparations, in house or at a named outside lab? And how are beyond-use dates assigned, with what stability data behind any date that stretches past the chapter's defaults?
That last one matters more for peptides than for most compounded drugs. A long beyond-use date on a reconstituted peptide is defensible only with stability testing of that formulation in that container. If the answer is "industry standard practice," the date is a guess with a label on it.
A flawlessly run 503A pharmacy still may not compound a peptide that fails the bulk substance conditions, and this is the question that most often puts a prescriber's name somewhere it should not be.
A bulk substance qualifies when it has a USP or NF monograph, when it is a component of an FDA-approved drug, or when it appears on the 503A Bulks List. Substances that were nominated but not yet decided fall under FDA's interim policy, which sorts them into three categories. Category 1 substances were nominated with enough information for FDA to evaluate them, and FDA does not intend to act against pharmacies that compound with them while the guidance conditions are met. Category 2 substances were also fully nominated, but FDA has identified significant safety risks and extends them no such policy. Category 3 substances arrived without enough information to evaluate.
Only Category 1 gives a pharmacy a workable basis for compounding a nominated peptide today. A pharmacy compounding a Category 2 substance is accepting enforcement risk, and the prescriber writing for it shares the exposure. The substances FDA removed from Category 2 earlier this year did not move to Category 1, and nominations made on or after January 7, 2025, are no longer sorted into categories at all.
Ask the pharmacy for the current status of the specific peptide and the source it relies on. The right answer points to FDA's own bulk substances page and its category attachment. Then check it yourself, because the categories are an enforcement policy FDA can change without notice, and a pharmacy's list can lag by months.
One more rule. A 503A pharmacy may not regularly compound what is essentially a copy of a commercially available drug. Where an approved version exists and is not in shortage, a compounded version needs a documented, patient-specific reason the approved product will not do.
All of the above collapses into one conversation with the pharmacist in charge. Keep the answers in the chart, next to the consent discussion.
A good pharmacy has heard every one of these before and answers in writing. The length of the pause is also an answer.
Some signals are disqualifying by themselves. A pharmacy marketing a peptide menu straight to patients with a telehealth prescriber attached is in a different business from the one you are shopping for. A pharmacy that will dispense without a patient-specific prescription while calling itself 503A is describing a violation out loud. A pharmacy that cannot name its bulk manufacturer, or buys from a vendor whose labels say "for research use only," cannot meet the 503A conditions. A pharmacy that lists Category 2 peptides as available has either not read the list or has decided the risk is yours.
Softer signals earn a second question rather than a verdict: "best" or "#1" in the page title with no accreditor named, a beyond-use date far longer than peers offer for the same preparation, or same-day turnaround on a sterile product that normally sits in quarantine until the test results come back.
People search for the best compounding pharmacy for peptides all the time, and most of the answers are pharmacies voting for themselves. We do not name one, for two reasons. Licensure runs state by state, so the right pharmacy for a patient in Texas may not be allowed to ship to one in California. And inspection files, accreditations, and FDA's category lists all move, so a recommendation that was sound in spring can be wrong by fall. The checklist above still works when the names change.
What we do teach is how to build the relationship. Peptavo's course includes the sourcing and compounding module this guide condenses, with accredited peptide CME attached, alongside the prescribing, consent, and monitoring work that surrounds it. For the broader legal picture, start with who can prescribe peptides, and the peptide consent form template carries the sourcing disclosure a compounded prescription calls for.
No. Compounded drugs are not FDA-approved, and FDA does not review them for safety, effectiveness, or quality before they are dispensed. A compounded peptide is lawful when the pharmacy, the prescription, and the bulk substance each meet the conditions in section 503A or 503B. Approval is a separate status that belongs only to manufactured drugs on FDA's approved list.
Many are, and the answer depends on the specific peptide and the pharmacy. The peptide has to qualify as a bulk substance, through a monograph, an approved drug, the 503A Bulks List, or Category 1 of FDA's interim policy, and the pharmacy has to be licensed in your patient's state and compounding on a patient-specific prescription. Our legality guide walks through each pathway and the state rules stacked on top.
Start at your state board of pharmacy's license lookup and filter for pharmacies with sterile compounding on their license. Cross-check candidates against the ACHC and NABP directories, and against FDA's outsourcing facility list if they claim 503B status. Colleagues in your specialty are the best source of names, and the checklist in this guide is how you confirm one.
A compounded peptide is prepared by a licensed pharmacy for a named patient from a bulk substance that meets federal conditions, under state and FDA oversight. A "research peptide" is a vial sold online labeled not for human use, with no prescription, no pharmacist, no sterility testing, and no legal basis for a patient to inject it. Same molecule, opposite sides of the law.